Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 13/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.37 |
| ▸ | MGMT | P16455 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3455309 | 0.85 | ADORA2A (0.43) | ADORA2AADORA1CCNA2CDK2CCNA1 | |
| SCHEMBL3455974 | 0.83 | ADORA2A (0.42) | MAPTADORA2AADORA1CCNA2CDK2 | |
| SCHEMBL3455589 | 0.80 | ADORA2A (0.55) | MAPTADORA2AADORA1ADORA2BPIK3R1 | |
| SCHEMBL3455145 | 0.78 | ADORA2A (0.46) | ADORA2AADORA1ADORA2BPIK3R1PIK3CA | |
| SCHEMBL13942226 | 0.77 | ADORA2A (0.49) | ADORA2AADORA1ADORA2BPIK3R1PIK3CA | |
| SCHEMBL5453909 | 0.77 | DHFR (0.51) | MAPTADORA2AADORA1ADORA2BPIK3R1 | |
| Hydrochloric Acid SCHEMBL3455706 | 0.76 | ADORA2A (0.48) | ADORA2AADORA1ADORA2BPIK3R1PIK3CA | |
| SCHEMBL3455110 | 0.74 | ADORA2A (0.58) | ADORA2AADORA1ADORA2BPIK3R1PIK3CA | |
| SCHEMBL3456020 | 0.74 | ADORA2A (0.52) | MAPTADORA2AADORA1ADORA2BPIK3R1 | |
| SCHEMBL3455545 | 0.72 | ADORA2A (0.54) | ADORA2AADORA1ADORA2BPIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2246344-A1 | Pyrimidine compounds and medicinal composition thereof | Eisai R&D Management Co., Ltd. (JP) | 2010-11-03 | — | — | EP | claimed |
| EP-2246344-A1 | Pyrimidine compounds and medicinal composition thereof | Eisai R&D Management Co., Ltd. (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | HARADA HITOSHI | 2009-01-29 | — | — | US | disclosed |
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | HARADA HITOSHI | 2009-01-29 | — | — | US | disclosed |
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | HARADA HITOSHI | 2009-01-29 | — | — | US | disclosed |
| US-7396836-B2 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| US-7396836-B2 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| US-7396836-B2 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| US-20050004149-A1 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1439175-A1 | PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | CBR3, AHR, HCCS | MAPT 3730/4885ADORA2A 539/4885ADORA1 328/4885 |
| US-20050004149-A1 | Pyrimidine compound and medicinal composition thereof | ADORA2B, ADORA2A, ADORA3 | MAPT 4776/4885ADORA2A 2/4885ADORA1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.